Switch to:
Also traded in: Austria, Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.86
ILMN's Cash-to-Debt is ranked higher than
62% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. ILMN: 1.86 )
Ranked among companies with meaningful Cash-to-Debt only.
ILMN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.69  Med: 1.73 Max: 16544
Current: 1.86
0.69
16544
Equity-to-Asset 0.56
ILMN's Equity-to-Asset is ranked lower than
51% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. ILMN: 0.56 )
Ranked among companies with meaningful Equity-to-Asset only.
ILMN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.55 Max: 0.94
Current: 0.56
0.36
0.94
Debt-to-Equity 0.41
ILMN's Debt-to-Equity is ranked higher than
51% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. ILMN: 0.41 )
Ranked among companies with meaningful Debt-to-Equity only.
ILMN' s Debt-to-Equity Range Over the Past 10 Years
Min: 0  Med: 0.47 Max: 1.5
Current: 0.41
0
1.5
Debt-to-EBITDA 1.27
ILMN's Debt-to-EBITDA is ranked higher than
71% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. ILMN: 1.27 )
Ranked among companies with meaningful Debt-to-EBITDA only.
ILMN' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.96  Med: 1.93 Max: 3.41
Current: 1.27
0.96
3.41
Interest Coverage 19.91
ILMN's Interest Coverage is ranked lower than
54% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. ILMN: 19.91 )
Ranked among companies with meaningful Interest Coverage only.
ILMN' s Interest Coverage Range Over the Past 10 Years
Min: 4.92  Med: 7.73 Max: 19.91
Current: 19.91
4.92
19.91
Piotroski F-Score: 6
Altman Z-Score: 14.75
Beneish M-Score: -2.77
WACC vs ROIC
9.23%
30.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 27.59
ILMN's Operating Margin % is ranked higher than
89% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. ILMN: 27.59 )
Ranked among companies with meaningful Operating Margin % only.
ILMN' s Operating Margin % Range Over the Past 10 Years
Min: 17.88  Med: 22.42 Max: 28.47
Current: 27.59
17.88
28.47
Net Margin % 20.88
ILMN's Net Margin % is ranked higher than
95% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. ILMN: 20.88 )
Ranked among companies with meaningful Net Margin % only.
ILMN' s Net Margin % Range Over the Past 10 Years
Min: 6.88  Med: 13.5 Max: 26.38
Current: 20.88
6.88
26.38
ROE % 22.22
ILMN's ROE % is ranked higher than
95% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. ILMN: 22.22 )
Ranked among companies with meaningful ROE % only.
ILMN' s ROE % Range Over the Past 10 Years
Min: 6.51  Med: 12.38 Max: 29.32
Current: 22.22
6.51
29.32
ROA % 12.20
ILMN's ROA % is ranked higher than
92% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. ILMN: 12.20 )
Ranked among companies with meaningful ROA % only.
ILMN' s ROA % Range Over the Past 10 Years
Min: 3.41  Med: 7 Max: 15.22
Current: 12.2
3.41
15.22
ROC (Joel Greenblatt) % 76.41
ILMN's ROC (Joel Greenblatt) % is ranked higher than
98% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. ILMN: 76.41 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ILMN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 56.69  Med: 78.88 Max: 133.65
Current: 76.41
56.69
133.65
3-Year Revenue Growth Rate 14.20
ILMN's 3-Year Revenue Growth Rate is ranked higher than
80% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. ILMN: 14.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ILMN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1  Med: 21.95 Max: 156.2
Current: 14.2
-1
156.2
3-Year EBITDA Growth Rate 27.30
ILMN's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ILMN: 27.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ILMN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 27.4 Max: 119.6
Current: 27.3
0
119.6
3-Year EPS without NRI Growth Rate 27.60
ILMN's 3-Year EPS without NRI Growth Rate is ranked higher than
74% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. ILMN: 27.60 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ILMN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 26.95 Max: 56.4
Current: 27.6
0
56.4
GuruFocus has detected 3 Warning Signs with Illumina Inc ILMN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ILMN's 30-Y Financials

Financials (Next Earnings Date: 2018-10-24 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

ILMN Guru Trades in Q3 2017

Ray Dalio 63,012 sh (+236.55%)
First Eagle Investment 400 sh (unchged)
Caxton Associates Sold Out
Ron Baron 444,335 sh (-0.94%)
Steven Cohen 62,800 sh (-1.10%)
Frank Sands 4,926,817 sh (-5.58%)
PRIMECAP Management 1,903,230 sh (-6.49%)
Vanguard Health Care Fund 1,920,681 sh (-27.97%)
Jim Simons 133,218 sh (-50.83%)
Spiros Segalas 1,523,457 sh (-20.79%)
» More
Q4 2017

ILMN Guru Trades in Q4 2017

Tom Gayner 1,000 sh (New)
Pioneer Investments 35,948 sh (New)
Joel Greenblatt 2,009 sh (New)
Steven Cohen 87,600 sh (+39.49%)
First Eagle Investment 400 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 1,887,360 sh (-0.83%)
Frank Sands 4,752,498 sh (-3.54%)
Ron Baron 414,734 sh (-6.66%)
Vanguard Health Care Fund 1,557,088 sh (-18.93%)
Jim Simons 43,818 sh (-67.11%)
Spiros Segalas 1,410,258 sh (-7.43%)
» More
Q1 2018

ILMN Guru Trades in Q1 2018

Mario Gabelli 4,770 sh (New)
Pioneer Investments 79,607 sh (+121.45%)
Ron Baron 420,580 sh (+1.41%)
Spiros Segalas 1,508,475 sh (+6.96%)
Tom Gayner 1,000 sh (unchged)
Steven Cohen Sold Out
Joel Greenblatt Sold Out
First Eagle Investment Sold Out
PRIMECAP Management 1,873,520 sh (-0.73%)
Frank Sands 4,463,446 sh (-6.08%)
Vanguard Health Care Fund 1,357,888 sh (-12.79%)
Jim Simons 18,218 sh (-58.42%)
» More
Q2 2018

ILMN Guru Trades in Q2 2018

Andreas Halvorsen 500,763 sh (New)
Paul Tudor Jones 16,039 sh (New)
Steven Cohen 85,900 sh (New)
Jim Simons 63,618 sh (+249.20%)
Pioneer Investments 132,350 sh (+66.25%)
Mario Gabelli 6,700 sh (+40.46%)
Ron Baron 429,790 sh (+2.19%)
Tom Gayner 1,000 sh (unchged)
Frank Sands 4,270,391 sh (-4.33%)
Vanguard Health Care Fund 1,214,488 sh (-10.56%)
PRIMECAP Management 1,126,843 sh (-39.85%)
Spiros Segalas 1,483,925 sh (-1.63%)
» More
» Details

Insider Trades

Latest Guru Trades with ILMN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Reduce -10.56%0.08%$228.17 - $292.07 $ 358.1637%1,214,488
Ron Baron 2018-06-30 Add 2.19%0.01%$228.17 - $292.07 $ 358.1637%429,790
Mario Gabelli 2018-06-30 Add 40.46%$228.17 - $292.07 $ 358.1637%6,700
Vanguard Health Care Fund 2018-03-31 Reduce -12.79%0.09%$209.54 - $253.91 $ 358.1652%1,357,888
Ron Baron 2018-03-31 Add 1.41%0.01%$209.54 - $253.91 $ 358.1652%420,580
Mario Gabelli 2018-03-31 New Buy0.01%$209.54 - $253.91 $ 358.1652%4,770
Joel Greenblatt 2018-03-31 Sold Out 0.01%$209.54 - $253.91 $ 358.1652%0
First Eagle Investment 2018-03-31 Sold Out $209.54 - $253.91 $ 358.1652%0
Vanguard Health Care Fund 2017-12-31 Reduce -18.93%0.16%$202.23 - $227.48 $ 358.1670%1,557,088
Ron Baron 2017-12-31 Reduce -6.66%0.03%$202.23 - $227.48 $ 358.1670%414,734
Joel Greenblatt 2017-12-31 New Buy0.01%$202.23 - $227.48 $ 358.1670%2,009
Tom Gayner 2017-12-31 New Buy$202.23 - $227.48 $ 358.1670%1,000
Vanguard Health Care Fund 2017-09-30 Reduce -27.97%0.28%$169 - $213.93 $ 358.1688%1,920,681
Ron Baron 2017-09-30 Reduce -0.94%$169 - $213.93 $ 358.1688%444,335
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:NYSE:BAX, XPAR:EI, TSE:4543, OCSE:COLO B, NYSE:WAT, NYSE:MTD, NYSE:RMD, TSE:7733, NAS:XRAY, NYSE:COO, XSWX:STMN, NAS:HOLX, NYSE:BDX, NYSE:STE, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD » details
Traded in other countries:ILMN.Austria, ILU.Germany, ILMN.Mexico,
Headquarter Location:USA
Illumina Inc engages in life science tools and machines for analyzing genetic material. The company primarily engages in microarray and genome sequencing machines and disposables. It also provides sequencing services through its products.

Illumina Inc is a major player in life science tools for analyzing genetic material. Revenue from microarray and genome sequencing machines and disposables make up most of the company's revenue, but approximately 10% of the company's sales come from sequencing services. Essentially all of Illumina's growth stems from the company's genome sequencing products, which include the company's high-throughput NovaSeq and HiSeq instruments in addition to its benchtop NextSeq, MiSeq, and MiniSeq, and iSeq product lines.

Guru Investment Theses on Illumina Inc

Baron Opportunity Fund Comments on Illumina - Feb 21, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell in the fourth quarter after reporting disappointing third quarter financial results. The third quarter shortfall was driven by weak high-throughput instrument sales. However, at the J.P. Morgan Healthcare Conference in January, Illumina announced an exciting new high-throughput sequencing platform, called NovaSeq, which has the potential in future years to deliver the world’s first $100 full human genome. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. (Neal Kaufman)



From Baron Funds' Baron Opportunity Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Illumina - Feb 13, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell almost 30% after reporting disappointing third quarter financial results. The shortfall was caused primarily by weak high-throughput instrument sales in North America and general weakness in Europe. Illumina’s growth is very much driven by new product introductions, and in 2016 sales suffered as the high- throughput instrument line reached the end of its life cycle. In early 2017, Illumina launched a new high- throughput sequencing platform that should re-accelerate growth. In addition, Grail, the start-up funded by Illumina which is developing a blood-based cancer screening test, announced it received capital commitments of $1 billion and would become one of Illumina’s largest customers over time. We continue to believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Asset Fund Comments on Illumina Inc. - Jan 30, 2017

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, fell after reporting disappointing financial results. The quarterly shortfall was driven by weak sales of its high-throughput instruments. We reduced the size of our position but continue to own the stock because we believe Illumina has a long runway for growth driven by increasing adoption of DNA sequencing in clinical markets such as cancer screening, diagnosis, and treatment. We are encouraged that the shares have had a meaningful recovery in early January, as the company provided encouraging earnings guidance for 2017 and launched a powerful, new DNA sequencing platform.



From Barron Asset Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina Inc. - Oct 25, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, contributed to performance in the third quarter. The company reported financial results that beat Wall Street expectations and reiterated guidance for the year. Unfortunately, after quarter end, Illumina pre-announced weaker-than-expected third quarter results and guided down its fourth quarter, and its stock has retreated. While we acknowledge that Illumina may be in a soft patch until we hit an inflection point in the adoption of genetic sequencing for actual patient care, with oncology being the largest opportunity, we continue to believe Illumina has strong moats around its DNA sequencing platform and a long runway for growth. (Neal Kaufman)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Illumina - Oct 21, 2016

Shares of Illumina, Inc. (NASDAQ:ILMN), the leading provider of DNA sequencing technology to academic and commercial laboratories, gained after the company reported financial results that exceeded Wall Street’s expectations. The results confirmed strong demand both for the company’s sequencing instruments in the Americas and China, as well as for its products in clinical applications, such as oncology screening and diagnosis. Management also demonstrated its ability to rein in expenses, which helped lead to accelerating EPS growth. We continue to believe Illumina has a long runway for growth, driven by increasing adoption of DNA sequencing technologies, particularly in clinical markets.



From Baron Funds' Barron Asset Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Illumina Inc

5 Stocks Beating the Market Illumina, Icahn Enterprises on the list
According to the GuruFocus All-in-One Guru Screener, the following stocks have outperformed the Standard & Poor's 500 Index over the past 12 months and were bought by gurus during the last quarter. Read more...
Inscripta Announces Strategic Acquisition of Solana Biosciences
Detailed Research: Economic Perspectives on Allete, Sterling Construction, Illumina, PROS, Altra Industrial Motion, and Pacific Biosciences of California — What Drives Growth in Today's Competitive Landscape
US Stocks With Positive Direction Tuesday Illumina rises on earnings
U.S. stock markets were higher in morning trading Tuesday, ahead of a positive report that the consumer confidence index rose to 127.4 in July from a revised 127.1 in the previous month. Read more...
Update: Lawsuit for Investors in NASDAQ: ILMN shares against Illumina, Inc. announced by Shareholders Foundation
US Stocks Green Monday International Flavors & Fragrances topped expectations
U.S. stock market indexes were in the green after oil prices climbed to more than $70 a barrel for the first time since 2014. Read more...
ILLUMINA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Illumina, Inc. - ILMN
Loxo Oncology and Illumina to Partner on Developing Next-Generation Sequencing-Based Pan-Cancer Companion Diagnostics
New Research Coverage Highlights Illumina, Vectren, Chemours, Fastenal, Norwegian Cruise Line, and Globalstar — Consolidated Revenues, Company Growth, and Expectations for 2018
Gayner Dumps Oil and Gas for a Bet on DNA Technology The guru apparently got turned off by weak earnings of industry leaders like Exxon Mobil
Investment guru Tom Gayner (TradesPortfolio) dumped his stake in two high-profile oil and gas companies for a position in a California-based company that provides DNA sequencing technology to academic and commercial labs. Read more...

Ratios

vs
industry
vs
history
PE Ratio 81.40
ILMN's PE Ratio is ranked lower than
90% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. ILMN: 81.40 )
Ranked among companies with meaningful PE Ratio only.
ILMN' s PE Ratio Range Over the Past 10 Years
Min: 32.28  Med: 70.64 Max: 302.86
Current: 81.4
32.28
302.86
Forward PE Ratio 58.82
ILMN's Forward PE Ratio is ranked lower than
95% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ILMN: 58.82 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 81.40
ILMN's PE Ratio without NRI is ranked lower than
88% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. ILMN: 81.40 )
Ranked among companies with meaningful PE Ratio without NRI only.
ILMN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 32.28  Med: 70.64 Max: 302.86
Current: 81.4
32.28
302.86
Price-to-Owner-Earnings 73.32
ILMN's Price-to-Owner-Earnings is ranked lower than
63% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. ILMN: 73.32 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
ILMN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 20.62  Med: 55.65 Max: 97.42
Current: 73.32
20.62
97.42
PB Ratio 16.17
ILMN's PB Ratio is ranked lower than
74% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. ILMN: 16.17 )
Ranked among companies with meaningful PB Ratio only.
ILMN' s PB Ratio Range Over the Past 10 Years
Min: 2.88  Med: 8.81 Max: 23.59
Current: 16.17
2.88
23.59
PS Ratio 17.08
ILMN's PS Ratio is ranked lower than
76% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. ILMN: 17.08 )
Ranked among companies with meaningful PS Ratio only.
ILMN' s PS Ratio Range Over the Past 10 Years
Min: 3.54  Med: 9.9 Max: 17.19
Current: 17.08
3.54
17.19
Price-to-Free-Cash-Flow 70.49
ILMN's Price-to-Free-Cash-Flow is ranked lower than
78% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. ILMN: 70.49 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ILMN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.31  Med: 45.64 Max: 127.5
Current: 70.49
13.31
127.5
Price-to-Operating-Cash-Flow 49.13
ILMN's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. ILMN: 49.13 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ILMN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.31  Med: 32.42 Max: 344.72
Current: 49.13
10.31
344.72
EV-to-EBIT 57.70
ILMN's EV-to-EBIT is ranked lower than
75% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. ILMN: 57.70 )
Ranked among companies with meaningful EV-to-EBIT only.
ILMN' s EV-to-EBIT Range Over the Past 10 Years
Min: 17  Med: 40.5 Max: 1825.9
Current: 57.7
17
1825.9
EV-to-EBITDA 48.75
ILMN's EV-to-EBITDA is ranked lower than
79% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. ILMN: 48.75 )
Ranked among companies with meaningful EV-to-EBITDA only.
ILMN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.6  Med: 32.6 Max: 222.2
Current: 48.75
12.6
222.2
EV-to-Revenue 16.62
ILMN's EV-to-Revenue is ranked lower than
73% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. ILMN: 16.62 )
Ranked among companies with meaningful EV-to-Revenue only.
ILMN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.8  Med: 9.8 Max: 17.4
Current: 16.62
2.8
17.4
PEG Ratio 2.80
ILMN's PEG Ratio is ranked higher than
60% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. ILMN: 2.80 )
Ranked among companies with meaningful PEG Ratio only.
ILMN' s PEG Ratio Range Over the Past 10 Years
Min: 0.67  Med: 1.8 Max: 13.16
Current: 2.8
0.67
13.16
Shiller PE Ratio 165.87
ILMN's Shiller PE Ratio is ranked lower than
99.99% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 52.49 vs. ILMN: 165.87 )
Ranked among companies with meaningful Shiller PE Ratio only.
ILMN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 99.02  Med: 243.6 Max: 3600
Current: 165.87
99.02
3600
Current Ratio 2.79
ILMN's Current Ratio is ranked higher than
78% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. ILMN: 2.79 )
Ranked among companies with meaningful Current Ratio only.
ILMN' s Current Ratio Range Over the Past 10 Years
Min: 0.99  Med: 4.38 Max: 60.21
Current: 2.79
0.99
60.21
Quick Ratio 2.49
ILMN's Quick Ratio is ranked higher than
82% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ILMN: 2.49 )
Ranked among companies with meaningful Quick Ratio only.
ILMN' s Quick Ratio Range Over the Past 10 Years
Min: 0.87  Med: 4.08 Max: 60.21
Current: 2.49
0.87
60.21
Days Inventory 127.03
ILMN's Days Inventory is ranked higher than
52% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. ILMN: 127.03 )
Ranked among companies with meaningful Days Inventory only.
ILMN' s Days Inventory Range Over the Past 10 Years
Min: 111.78  Med: 132.78 Max: 147.41
Current: 127.03
111.78
147.41
Days Sales Outstanding 46.46
ILMN's Days Sales Outstanding is ranked higher than
70% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. ILMN: 46.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
ILMN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.46  Med: 63.31 Max: 86.41
Current: 46.46
46.46
86.41
Days Payable 56.30
ILMN's Days Payable is ranked higher than
67% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. ILMN: 56.30 )
Ranked among companies with meaningful Days Payable only.
ILMN' s Days Payable Range Over the Past 10 Years
Min: 51.84  Med: 63.53 Max: 93.62
Current: 56.3
51.84
93.62

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.80
ILMN's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. ILMN: -0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ILMN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -13.6  Med: -5.1 Max: -0.3
Current: -0.8
-13.6
-0.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 4477.01
ILMN's Price-to-Net-Cash is ranked lower than
99.99% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. ILMN: 4477.01 )
Ranked among companies with meaningful Price-to-Net-Cash only.
ILMN' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.14  Med: 25.04 Max: 4477.01
Current: 4477.01
2.14
4477.01
Price-to-Net-Current-Asset-Value 62.94
ILMN's Price-to-Net-Current-Asset-Value is ranked lower than
84% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. ILMN: 62.94 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ILMN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.95  Med: 12.78 Max: 2050.89
Current: 62.94
1.95
2050.89
Price-to-Tangible-Book 23.71
ILMN's Price-to-Tangible-Book is ranked lower than
75% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. ILMN: 23.71 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ILMN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.17  Med: 8.41 Max: 461.34
Current: 23.71
1.17
461.34
Price-to-Intrinsic-Value-Projected-FCF 5.73
ILMN's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
81% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. ILMN: 5.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ILMN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.53  Med: 4.44 Max: 42.17
Current: 5.73
1.53
42.17
Price-to-Intrinsic-Value-DCF (Earnings Based) 7.61
ILMN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
99.99% of the 17 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. ILMN: 7.61 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
ILMN' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 3.21  Med: 3.87 Max: 5.93
Current: 7.61
3.21
5.93
Price-to-Median-PS-Value 1.73
ILMN's Price-to-Median-PS-Value is ranked lower than
55% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. ILMN: 1.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ILMN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 0.99 Max: 66.74
Current: 1.73
0.4
66.74
Price-to-Peter-Lynch-Fair-Value 3.26
ILMN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
50% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. ILMN: 3.26 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
ILMN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.37  Med: 2.55 Max: 9.54
Current: 3.26
1.37
9.54
Price-to-Graham-Number 9.26
ILMN's Price-to-Graham-Number is ranked lower than
99.99% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.98 vs. ILMN: 9.26 )
Ranked among companies with meaningful Price-to-Graham-Number only.
ILMN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.52  Med: 6.59 Max: 49.18
Current: 9.26
3.52
49.18
Earnings Yield (Greenblatt) % 1.73
ILMN's Earnings Yield (Greenblatt) % is ranked higher than
67% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. ILMN: 1.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ILMN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 2.5 Max: 5.9
Current: 1.73
0.1
5.9
Forward Rate of Return (Yacktman) % 20.97
ILMN's Forward Rate of Return (Yacktman) % is ranked higher than
93% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. ILMN: 20.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
ILMN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.5  Med: 21 Max: 23.3
Current: 20.97
-0.5
23.3

More Statistics

Revenue (TTM) (Mil) $3,103.00
EPS (TTM) $ 4.40
Beta1.05
Volatility23.10%
52-Week Range $196.00 - 360.63
Shares Outstanding (Mil)147.00

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 3,284 3,703 4,231
EBIT (Mil $) 839 987
EBITDA (Mil $) 1,050 1,245 1,476
EPS ($) 4.82 5.42 6.45
EPS without NRI ($) 4.82 5.42 6.45
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.94%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}